Determinants of durable humoral and T cell immunity in myeloma patients following COVID ‐19 vaccination
European Journal of Haematology · 2024-04 · 112 (4) · 547-553
DOI: 10.1111/ejh.14143 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Haematology, online erschienen am 20.12.2023. Verfasst von Clement Twumasi und 22 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Imperial College London, Oxford, UK. Hauptthemen laut MEDLINE: COVID-19, Multiple Myeloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Blood Cancer Vaccine Consortium, Myeloma UK, Janssen UK.
Abstract (Originalsprache)
Objective
To describe determinants of persisting humoral and cellular immune response to the second COVID‐19 vaccination among patients with myeloma.
Methods
This is a prospective, observational study utilising the RUDYstudy.org platform. Participants reported their second and third COVID‐19 vaccination dates. Myeloma patients had an Anti‐S antibody level sample taken at least 21 days after their second vaccination and a repeat sample before their third vaccination.
Results
60 patients provided samples at least 3 weeks (median 57.5 days) after their second vaccination and before their third vaccination (median 176.0 days after second vaccine dose). Low Anti‐S antibody levels (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Imperial College London, Oxford, UK.
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
- Bath Royal United Hospitals, Oxford University Hospitals NHS Trust, Bath, UK.
- Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.
- The Botnar Research Centre, Headington, UK.
- Medical Sciences Division, University of Oxford, Oxford, UK.
ORCID-Profile: Clement Twumasi, Sally Moore, Ross Sadler, Sherin Varghese, Alison Turner, Gaurav Agarwal, Stella Bowcock, Udo Oppermann, Gordon Cook, Mark Drayson, Supratik Basu, Sarah Gooding, Muhammad K Javaid, Karthik Ramasamy
Förderung
- Blood Cancer Vaccine Consortium
- Myeloma UK
- Janssen UK
- National Institute for Health Research
- National Institute for Health and Care Research
Zitieren
APA
Twumasi, C., Moore, S., Sadler, R., Jeans, S., Varghese, S., Turner, A., Agarwal, G., Larham, J., Gray, N., Carty, O., Barrett, J., Bowcock, S., Oppermann, U., Gamble, V., Cook, G., Kyriakou, C., Drayson, M., Basu, S., McDonald, S., …, & Ramasamy, K. (2024). Determinants of durable humoral and T cell immunity in myeloma patients following COVID ‐19 vaccination. European Journal of Haematology, 112(4), 547-553. https://doi.org/10.1111/ejh.14143
Vancouver
Twumasi C, Moore S, Sadler R, Jeans S, Varghese S, Turner A, et al. Determinants of durable humoral and T cell immunity in myeloma patients following COVID ‐19 vaccination. European Journal of Haematology. 2024;112(4):547-553. doi:10.1111/ejh.14143
BibTeX
@article{Twumasi2024,
author = {Twumasi, Clement and Moore, Sally and Sadler, Ross and Jeans, Sally and Varghese, Sherin and Turner, Alison and Agarwal, Gaurav and Larham, Jemma and Gray, Nathanael and Carty, Oluremi and Barrett, Joe and Bowcock, Stella and Oppermann, Udo and Gamble, Vicky and Cook, Gordon and Kyriakou, Chara and Drayson, Mark and Basu, Supratik and McDonald, Sarah and McKinley, Shelagh and Gooding, Sarah and Javaid, Muhammad K and Ramasamy, Karthik},
title = {Determinants of durable humoral and T cell immunity in myeloma patients following COVID ‐19 vaccination},
journal = {European Journal of Haematology},
year = {2024},
volume = {112},
number = {4},
pages = {547--553},
doi = {10.1111/ejh.14143}
}
EUVIMED